ArticleThe EMBO journal2009
Cancer induction by restriction of oncogene expression to the stem cell compartment.
Article in The EMBO journal, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 129 citations in OpenAlex.
- Cell Lineage Affiliation During Hematopoiesis.International journal of molecular sciences · 2025Review
- Hematopoietic and Chronic Myeloid Leukemia Stem Cells: Multi-Stability versus Lineage Restriction.International journal of molecular sciences · 2022Review
- The Social Norm of Hematopoietic Stem Cells and Dysregulation in Leukemia.International journal of molecular sciences · 2022Review
- Oncogenes and the Origins of Leukemias.International journal of molecular sciences · 2022Review
- Lessons to cancer from studies of leukemia and hematopoiesis.Frontiers in cell and developmental biology · 2022Review
- Oncogenes, Proto-Oncogenes, and Lineage Restriction of Cancer Stem Cells.International journal of molecular sciences · 2021Review
- Hematopoietic Stem Cells: Nature and Niche Nurture.Bioengineering (Basel, Switzerland) · 2021Review
- The RARγ Oncogene: An Achilles Heel for Some Cancers.International journal of molecular sciences · 2021Review
- The Cancer Genome: Paradigm or Paradox?Cancers · 2021Article
- Risk Factors for Childhood Leukemia: Radiation and Beyond.Frontiers in public health · 2021Review
- Lineage Decision-Making within Normal Haematopoietic and Leukemic Stem Cells.International journal of molecular sciences · 2020Review
- Insights into the prenatal origin of childhood acute lymphoblastic leukemia.Cancer metastasis reviews · 2020Review
- TIP5 primes prostate luminal cells for the oncogenic transformation mediated byProceedings of the National Academy of Sciences of the United States of America · 2020Article
- Evidence for immortality and autonomy in animal cancer models is often not provided, which causes confusion on key issues of cancer biology.Journal of Cancer · 2020Review
- Are Leukaemic Stem Cells Restricted to a Single Cell Lineage?International journal of molecular sciences · 2019Review
- Article
- Epigenetic Priming in Childhood Acute Lymphoblastic Leukemia.Frontiers in cell and developmental biology · 2019Review
- Lmo2 expression defines tumor cell identity during T-cell leukemogenesis.The EMBO journal · 2018Article
- The Making of Leukemia.International journal of molecular sciences · 2018Review
- Loss of Pax5 Exploits Sca1-BCR-ABLCancer research · 2018Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In human cancers, all cancerous cells carry the oncogenic genetic lesions. However, to elucidate whether cancer is a stem cell-driven tissue, we have developed a strategy to limit oncogene expression to the stem cell compartment in a transgenic mouse setting. Here, we focus on the effects of the BCR-ABLp210 oncogene, associated with chronic myeloid leukaemia (CML) in humans. We show that CML phenotype and biology can be established in mice by restricting BCR-ABLp210 expression to stem cell antigen 1 (Sca1)(+) cells. The course of the disease in Sca1-BCR-ABLp210 mice was not modified on STI571 treatment. However, BCR-ABLp210-induced CML is reversible through the unique elimination of the cancer stem cells (CSCs). Overall, our data show that oncogene expression in Sca1(+) cells is all that is required to fully reprogramme it, giving rise to a full-blown, oncogene-specified tumour with all its mature cellular diversity, and that elimination of the CSCs is enough to eradicate the whole tumour.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.